Illumina's stock has seen a modest increase in its Fair Value Estimate, rising from $113.58 to $117.74. This reflects improved analyst confidence in the company's future prospects. This change comes amid stronger than expected quarterly results and expanding opportunities, but also ongoing uncertainties in global demand and sector outlook. Stay tuned to learn how you can keep ahead of Illumina’s evolving market narrative as new developments arise.

Stay updated as the Fair Value for Illumina shifts by adding it to your watchlist or portfolio. Alternatively, explore our Community to discover new perspectives on Illumina.

Analyst commentary on Illumina continues to reflect mixed sentiment, balancing optimism about execution and growth with reservations about near-term uncertainties and sector challenges.

???? Bullish Takeaways

Piper Sandler raised its price target on Illumina to $195 from $185 and maintained an Overweight rating. The firm highlighted the positive impact of the company’s recent quarterly results as a reason for increased confidence.

Evercore ISI analyst Vijay Kumar increased the price target to $142 from $132 and kept an Outperform rating, noting Illumina’s Q3 results exceeded expectations due to strong operational management and cost efficiencies.

Both Piper Sandler and Evercore ISI underscored Illumina’s effective execution amid challenging conditions. However, Evercore ISI noted that valuation and persistent hurdles in regions such as China remain important to monitor.

???? Bearish Takeaways

Barclays analyst Luke Sergott lifted the price target to $100 from $95 but maintained an Underweight rating, expressing caution about the lack of visibility into Illumina’s business trajectory.

RBC Capital revised its price target to $124 from $126 and kept an Outperform rating but updated its model with more conservative assumptions. The firm cited overall sector weakness and a delayed rebound as factors for restraint.

Bearish and neutral analysts continue to focus on near-term headwinds, ongoing industry pressures, and uncertainties around broader healthcare sector performance as influencing factors in their outlook on Illumina’s valuation.

Do your thoughts align with the Bull or Bear Analysts? Perhaps you think there's more to the story. Head to the Simply Wall St Community to discover more perspectives or begin writing your own Narrative!

Illumina raised its 2025 earnings guidance, projecting revenue between $4.27 billion and $4.31 billion. This is $20 million higher at the midpoint than previous expectations.

The Chinese Ministry of Commerce will lift its export ban on Illumina from November 10. However, Illumina remains on the Unreliable Entities List, meaning purchases of its instruments in China will still require government approval.

Illumina launched BioInsight, a new AI-driven business that enables partners in research and pharmaceuticals to analyze large-scale multiomic data. This supports advances in drug discovery and disease understanding.

The company expanded its proteomics offerings, with Illumina Protein Prep now available in 16 sites globally. This enhances research efforts in cancer, cardiometabolic, and immunologic diseases.

The Fair Value Estimate has risen modestly from $113.58 to $117.74, reflecting higher analyst confidence in future prospects.

The Discount Rate increased slightly from 7.60% to 8.03%, signaling a small rise in the perceived risk associated with Illumina's equity.

Revenue Growth expectations have improved, with estimates moving from 4.01% to 4.17%.

The Net Profit Margin was nearly stable, showing a slight decrease from 17.80% to 17.74%.

The Future P/E Ratio has increased from 22.57x to 23.65x, which indicates that investors anticipate somewhat higher earnings multiples going forward.

Narratives are a smarter, more dynamic way to invest. They let you connect Illumina’s story to a specific financial forecast and Fair Value, so you can see not only the numbers but also the reasoning behind them. On Simply Wall St’s Community page, millions of investors use Narratives to monitor changes and compare Fair Value to price, helping them decide when to buy or sell as new events unfold.

Eager to understand Illumina’s full story? Read the original Narrative on Illumina and follow for:

Deep dives into how China’s evolving regulations and market recovery could impact Illumina’s long-term growth momentum.

Insight on recurring revenue drivers from clinical genomics and next-generation sequencing, plus the effect of ongoing innovation and efficiency gains.

Analysis of key risks such as rising competition, regulatory changes, and market uncertainties, as well as what these mean for Illumina’s earnings outlook.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include ILMN.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com